Article Sidebar

PDF
Date Published: 26/05/2023
Abstract Views: 134
Views PDF: 113
DOI: https://doi.org/10.51298/vmj.v526i1B.5447
Issue
Vol. 526 No. 1B (2023)
Section
Các bài báo
How to Cite
Lê, N. H. ., Nguyễn, H. T. ., Cao , H. P. ., Nguyễn, V. B. ., & Nguyễn, M. H. . (2023). DIFFERENCE IN IMMUNE RESPONSE BETWEEN COVID-19 VACCINES AND ESTIMATED HALF-LIFE OF ANTI-SPIKE SARS-COV-2 ANTIBODIES. Vietnam Medical Journal, 526(1B). https://doi.org/10.51298/vmj.v526i1B.5447

DIFFERENCE IN IMMUNE RESPONSE BETWEEN COVID-19 VACCINES AND ESTIMATED HALF-LIFE OF ANTI-SPIKE SARS-COV-2 ANTIBODIES

Ngọc Hùng Lê1,2,, Hữu Tùng Nguyễn1,3, Hùng Phú Cao 1, Văn Bắc Nguyễn1, Mạnh Hòa Nguyễn1
1 Tam Tri hospital
2 Phan Chu Trinh university
3 Phan CHu Trinh university

Main Article Content

Abstract

Aims: The purpose of study was to provide information on the immune response to the SARS-CoV-2 vaccine in healthy Vietnamese, the decrease of anti-spike antibody levels over time and the half-life. Methods: Investigation on 312 healthy persons anti-spike antibody levels after the 2nd dose of SARS-COV-2 vaccine of 6 vaccine regimens: AstraZeneca, Pfizer, Moderna, Verocell, AstraZeneca-Pfizer, and Moderna-Pfizer. Results: Rank vaccines from high to low antibody level as Pfizer>Moderna> AstraZeneca> Verocell. Verocell had the lowest antibody concentration, 26 U/mL (median). Hybrid combination AstraZeneca-Pfizer was the best. There was a decrease in antibody levels over time, in AstraZeneca vaccine anti-spike antibody in 91-120 days after the 2nd dose vaccine being lower than those in 1-30 days (p< 0.05). The estimated half-lives of anti-spike antibodies varied from 2.2 to 2.5 months for AstraZeneca, AstraZeneca-Pfizer and Moderna, 3.2 months for Pfizer, and longest as 6.4 months for Pfizer-Moderna combination, and shortest 1.9 months for Verocell. Conclusion: There was  a difference in anti-spike antibody responses between first-generation COVID-19 vaccines. The half-life of the anti-spike antibody of vaccine was documented.

Article Details

Keywords

COVID-19 vaccines; half-life; Anti-SARS-CoV-2 Spike Antibody; hybrid combination of vaccines

References

1. USC Student Health. List of Accepted vaccines/boosters, 2021. https:// studenthealth.usc.edu/list-of-accepted-vaccines.
2. Naranjargal J. Dashdorj, Oliver F. Wirz, Katharina Roltgen, Emily Haraguchi, et al. Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia. Cell Host & Microbe 29, 1738–1743, December 8, 2021.
3. Jan Van Elslande, Lien Gruwier, Lode Godderis, Pieter Vermeersch. Estimated Half-Life of SARS-CoV-2 Anti-Spike Antibodies More Than Double the Half-Life of Anti-nucleocapsid Antibodies in Healthcare Workers. Clinical Infectious Diseases, Volume 73, Issue 12, 15 December 2021, Pages 2366–2368, https://doi.org/10.1093/cid/ciab219.
4. Wikipedia. COVID-19 pandemic in Viet Nam. https://en.wikipedia.org/wiki/COVID-19_pandemic_in_Vietnam
5. Sarah E. Wheeler, Galina V. Shurin, Mary Yost, Adam Anderson, Lisa Pinto, Alan Wells, Michael R. Shurina. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. Microbiol Spectr 9:e00341-21. https://doi.org/ 10.1128/Spectrum.00341-21.
6. Stuart ASV, Shaw RH, Liu X, et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet 2021 (published online 6 Dec 2021)..
7. Ewen Callaway. Mix-and-match COVID vaccines trigger potent immune response. https: //www.nature.com/articles/d41586-021-01359-3.
8. Reuters. Mixing Pfizer, AstraZeneca COVID-19 shots with Moderna gives better immune response-UK study. https://www.reuters.com/ business/healthcare-pharmaceuticals/mixing-pfizer-astraz-covid-19-shots-with-moderna-gives-better-immune-response-uk-2021-12-06/.